Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Symposia on ‘Facial and Vocal Activity as Transdiagnostic Markers of CNS Illness and Treatment Response’ at the 2021 Society of Biological Psychiatry Annual Meeting April 29 through May 01, 2021
Redenlab’s Chief Science Officer (Prof Adam Vogel) presents at the symposia on Facial and Vocal Markers of CNS function, “Speech is a Sensitive Marker of Neuropsychiatric and Neurodegenerative Conditions (in the Right Context)” at 2021…
Speech and language deficits are central to SETBP1 haploinsufficiency disorder
Published in the European Journal of Human Genetics we expand the linguistic phenotype associated with SETBP1 LoF syndrome (SETBP1 haploinsufficiency disorder), revealing a striking speech presentation that implicates both motor (CAS, dysarthria) and language (phonological errors) systems, with CAS (80%) being the most common diagnosis.
Introducing Redenlab’s new Science Lead, Dr Gustavo Noffs MD, PhD
Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.
Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Accuracy of commercially available cloud based speech to text is dramatically affected by dysarthria severity
Our paper on Automatic speech recognition in neurodegenerative disease was recently published in International Journal of Speech Technology. Automatic speech recognition (ASR) could potentially improve communication by providing transcriptions of speech in real time. ASR…
SpeechATAXIA- a multinational, multilanguage consortia for speech in hereditary ataxias – powered by Redenlab
SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.
Upcoming webinar: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?
Redenlab CSO, Adam Vogel, will be presenting at the upcoming joint webinar with the European Reference Network for rare or low prevalence complex diseases, Neurological Diseases (ERN-RND), Neuromuscular Dieseases (ERN EURO-NMD), and European Academy of…
CLOSED – Job Opportunity: Software Developer.
The Position Redenlab is seeking an experienced Software Developer. Redenlab is one of the world’s leading providers of speech and language tests for use in human research trials. Redenlab provides its products and services to…
Upcoming webinar: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?
Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?